Immunodiagnostic Systems Holdings plc provided earnings guidance for the year ended March 31, 2014 and for the year fiscal year 2015. For the year, the company's total revenues are expected to be £52.3 million compared to £49.8 million reported in the year 2012-2013, representing 5% growth. The increase in revenue was primarily driven by the continued growth in automated revenue of 21%, compared to the prior year. Manual revenue declined by 18% over the same period. Adjusted EBIT, before exceptional items, is expected to be marginally ahead of the prior year adjusted EBIT compared to £9.8 million reported in the year 2012-2013.

The company announced that execution of the strategic initiatives, the company expected to lead to continued modest revenue growth in 2014-2015 counteracted to some degree by the effect of operating cost investment made in 2013-2014.